News S3-E38.6 – From the Vault: Patient-Focused Drug Development from Global Liver Institute Jul 31, 2022 S3-E38.5 – From the Vault: NAIL-NIT tackles NAS Score Challenges Jul 31, 2022 S3-E38.4 – From the Vault: NITs & Advancing NASH Therapy at AASLD 2021 Jul 30, 2022 S3-E38.3 – From the Vault: Learning About Stellate Cells and Fibrosis at Paris NASH Jul 30, 2022 S3-E38.2 – From the Vault: Scott Friedman on Fibrosis and Precision Medicine Jul 30, 2022 S3-E38.1 – From the Vault: Why NASH Drug Trials Fail Jul 30, 2022 S3-E38.1 – Looking back Through the Vault: Why NASH Drug Trials Fail Jul 29, 2022 S3-E38 – SurfingNASH 2nd Anniversary: Buzzsprout, Download Barriers and More! Jul 28, 2022 S3-E37.5 – The Need to Focus on NASH Cirrhosis Patients Jul 24, 2022 S3-E37.4 – The “Pincer Movement” In Cirrhosis Technology: Patient Support vs High-End MedTech Jul 24, 2022 S3-E73.3 – Where Is The Next Cirrhosis Breakthrough? Jul 24, 2022 S3-E37.2 – Can Today’s Medicines Cause Fibrosis Regression in Cirrhosis Patients? Jul 24, 2022 « Older Entries Next Entries »
S3-E37.4 – The “Pincer Movement” In Cirrhosis Technology: Patient Support vs High-End MedTech Jul 24, 2022
